Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/40150

Full metadata record
DC FieldValueLanguage
dc.contributor.authorMachado, D.por
dc.contributor.authorCastro, J.por
dc.contributor.authorOliveira, Ana Palmeira depor
dc.contributor.authorOliveira, José Martinez depor
dc.contributor.authorCerca, Nunopor
dc.date.accessioned2016-02-06T12:08:59Z-
dc.date.available2016-02-06T12:08:59Z-
dc.date.issued2016-01-20-
dc.identifier.citationMachado, D.; Castro, J.; Palmeira-de-Oliveira, Ana; Martinez-de-Oliveira, José; Cerca N, Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Frontiers in Microbiology, 6(1528), 1-13, 2016por
dc.identifier.issn1664-302Xpor
dc.identifier.urihttp://hdl.handle.net/1822/40150-
dc.description.abstractBacterial vaginosis (BV) is the most common genital tract infection in women during their reproductive years and it has been associated with serious health complications, such as preterm delivery and acquisition or transmission of several sexually transmitted agents. BV is characterized by a reduction of beneficial lactobacilli and a significant increase in number of anaerobic bacteria, including Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp., Bacteroides spp. and Prevotella spp.. Being polymicrobial in nature, BV etiology remains unclear. However, it is certain that BV involves the presence of a thick vaginal multi-species biofilm, where G. vaginalis is the predominant species. Similar to what happens in many other biofilm-related infections, standard antibiotics, like metronidazole, are unable to fully eradicate the vaginal biofilm, which can explain the high recurrence rates of BV. Furthermore, antibiotic therapy can also cause a negative impact on the healthy vaginal microflora. These issues sparked the interest in developing alternative therapeutic strategies. This review provides a quick synopsis of the currently approved and available antibiotics for BV treatment while presenting an overview of novel strategies that are being explored for the treatment of this disorder, with special focus on natural compounds that are able to overcome biofilm-associated antibiotic resistance.por
dc.description.sponsorshipResearch on BV biofilms in NC laboratory is supported by funding from the Fundação para a Ciência e a Tecnologia (FCT) strategic project of unit UID/BIO/04469/2013. DM and JC acknowledge the FCT fellowships SFRH/BD/87569/2012 and SFRH/BD/93963/2013 respectively. NC is an Investigador FCT.por
dc.language.isoengpor
dc.publisherFrontiers Mediapor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147337/PTpor
dc.relationSFRH/BD/87569/2012por
dc.relationSFRH/BD/93963/2013por
dc.rightsopenAccesspor
dc.subjectBacterial vaginosispor
dc.subjectBiofilmspor
dc.subjectGardnerella vaginalispor
dc.subjectAntibioticspor
dc.subjectEmerging therapiespor
dc.titleBacterial vaginosis biofilms: challenges to current therapies and emerging solutionspor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttp://journal.frontiersin.org/journal/microbiologypor
dc.commentsCEB33756por
sdum.publicationstatuspublishedpor
oaire.citationStartPage1por
oaire.citationEndPage13por
oaire.citationIssue1528por
oaire.citationTitleFrontiers in Microbiologypor
oaire.citationVolume6por
dc.date.updated2016-01-24T16:08:27Z-
dc.identifier.essn1664-302X-
dc.identifier.doi10.3389/fmicb.2015.01528por
dc.subject.wosScience & Technologypor
sdum.journalFrontiers in Microbiologypor
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_33756_1.pdf326,37 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID